This inventor holds 2 USPTO granted patents. Top assignee: Novartis Ag. Active years: 2010-2012.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Allschwil, CH (2010)
- Basel, CH (2012)
Company Filing History:
Years Active: 2010-2012
Title: The Innovations of Emil Pfenninger in Chemokine Research
Introduction
Emil Pfenninger, an accomplished inventor based in Basel, Switzerland, has made significant contributions to the field of biomedical research. With a focus on chemokine receptor antagonists, Pfenninger holds two patents that showcase his innovative advancements in pharmaceutical chemistry. His work at Novartis AG highlights his dedication to improving healthcare through scientific innovation.
Latest Patents
Pfenninger's latest patents are centered around chemokine receptor antagonists. Both patents describe a compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof, wherein the variants R, R9, Z, X, Q, and Y are meticulously defined in the specification. These compounds have the potential to play a critical role in therapeutic applications, providing new avenues for the treatment of various diseases.
Career Highlights
Throughout his career, Emil Pfenninger has demonstrated a profound understanding of pharmaceutical sciences and a commitment to advancing medical technology. His tenure at Novartis AG has allowed him to contribute to impactful research and development projects that aim to enhance patient outcomes. Pfenninger's focus on chemokine research places him at the forefront of innovative therapeutic strategies.
Collaborations
Pfenninger has collaborated with notable colleagues such as Philipp Janser and Hans Juerg Wuethrich. These partnerships foster a productive environment for research, awareness, and innovation, enabling the sharing of ideas that further advance their collective understanding in the field of chemokine receptor antagonism.
Conclusion
Emil Pfenninger's work in chemokine receptor antagonists reflects his dedication to innovation in the pharmaceutical industry. His contributions and collaborations at Novartis AG position him as a key figure in the pursuit of transformative medical solutions. As research continues to evolve, the advancements brought forth by inventors like Pfenninger are crucial for the future of medicine.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile